OTCBB Watchlist – Neurologix Phase II Trials Data for its Parkinson’s Disease Therapy
  • Lpath Inc. surged 66% over the last month on solid progress of iSONEP trials
  • FDA News; Cell Terapeutics stumbles on Delay in Pixantrone Approval
  • " />

    OTCBB Hot Stock – Brainstorm Gains 45% on Clinical Trials Approval

    Brainstorm Cell Therapeutics Inc. (OTC BB: BCLI) soared 45% over the last three trading days and closed the October 11 session at $0.29.  The company is likely to begin clinical trials of its stem cell treatment for the neurological disease amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease, after receiving clearance from Israel’s Ministry of Health. The trading volume has grown exponentially over the last trading days, exceeding 1 million shares on October 11. The company’s average daily trading volume ranged around 100,000 shares over the last three months.

    BrainStorm is a research and development company developing stem cell therapeutic products based on patent pending technology called NurOwn™. The company’s autologous stem cell-therapy seeks to repair and support degenerated tissues by processing adult human bone marrow mesenchymal stem cells, inducing them to differentiate into supportive neurological cells, and transplanting the cells back into the site of damage. BrainStorm’s scientific team was among the first to have successfully demonstrated the physiological release of dopamine from in vitro differentiated bone marrow cells. Moreover, in research conducted by this team, implantation of these cells into the brains of animal models that had been induced to Parkinsonian behavior markedly improved their symptoms.

    The company holds exclusive worldwide rights to commercialize the technology through a licensing agreement with Ramot, the technology transfer company of Tel Aviv University. The agreement also provides for further research, funded by BrainStorm, to be performed by Professor Melamed, Dr. Offen and members of their research team at the Felsenstein Medical Research Center. The results of this research are licensed to BrainStorm under the terms of the license agreement.

    The company’s current focus is on Lou Gehrig’s disease, which could allow a faster movement through the research pipeline, because it is terminal and considered an “orphan” or rare disease. However, its technology has promise for treating several other diseases, including Parkinson’s disease, Multiple Sclerosis, spinal cord injuries, Huntington’s disease and stroke.

    The recent announcement that the Israeli Ministry of Health granted clearance for a phase I/II clinical trial using the company’s autologous NurOwn™ stem-cell therapy in patients with Lou Gehrig’s disease represents a huge milestone for BrainStorm and marks the transition to clinical trials. The company plans to conduct the investigations in cooperation with Hadassah Medical Center.

    The initial phase of the study is designed to establish the safety of NurOwn™ and will later be expanded to assess efficacy. The trials are expected to begin following validation of sterility tests requested by the MOH and screening of patients for the trial and could commence by the end of 2010.

    BrainStorm’s stem-cell treatment represents a new approach that could help in several neurological diseases; the eventual positive results from the investigation would contribute to a significant appreciation of BrainStorm’s stock price.

    • Need fast service and cheap rates from a broker? Click here to see my favorite place to trade BCLI
    • Want more? Check out the message board buzz for BCLI
    • See what newsletters are recommending this stock pick
    • Get breaking news alerts on this stock:  http://thestockmarketwatch.com/

    About Microstockprofit.com

    Microstockprofit.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or penny stock market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.

    Microstockprofit.com Disclaimer

    This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Microstockprofit.com is a wholly owned subsidiary of BlueWave Advisors.

    While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Leave a Reply

    Your email address will not be published. Required fields are marked *